# Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Source: https://onco.cc/trials/nct06810544/  
OnCo record `nct06810544` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TNG456, Abemaciclib in non-small-cell lung cancer and small-cell lung cancer, run by Tango Therapeutics, Inc., now recruiting.

## Summary

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss is a phase 1/2 interventional study registered as NCT06810544 by Tango Therapeutics, Inc., with 191 participants planned, started 2025-03-24 and due to reach its primary completion in 2027-03-31. Interventions recorded: TNG456, abemaciclib. Conditions listed: Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06810544
- Phase: 1/2
- Setting: A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Sponsor: Tango Therapeutics, Inc.
- Enrolled: 191

## Sources

- ClinicalTrials.gov NCT06810544: https://clinicaltrials.gov/study/NCT06810544

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [TNG456](https://onco.cc/drugs/tng456/)
- companies: [Tango Therapeutics](https://onco.cc/companies/tango-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06810544.json